SLC5A2 and hydrops fetalis: The trial was ended early due to loss of funding, and thus its primary outcome was changed to compare the total number of cardiovascular deaths, HF hospitalizations and urgent visits for HF between sotagliflozin and placebo (Table 2).23 With regard to kidney outcomes, a kidney composite secondary outcome (including ≥50% decline in eGFR from baseline for ≥30 days, long-term dialysis, kidney transplant or sustained eGFR <15 mL/min/1.73 m2 for ≥30 days) trended toward benefit for SGLT2 inhibition (HR 0.71; 95% CI 0.46–1.08).23